Lakefront Biotherapeutics (LKFT) EBT (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly EBT of $16.3 million for Q1 2026, up 109.93% year-over-year from $7.8 million in Q1 2025, and down 98.21% quarter-over-quarter from $911.6 million in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) EBT (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported EBT for 13 consecutive years, with $16.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 109.93% year-over-year to $16.3 million; the TTM figure through Mar 2026 stood at $541.1 million (up 378.01% YoY), while the FY2025 annual figure was $350.2 million, up 10723.83% from the prior year.
- EBT fell to $16.3 million in Q1 2026 per LKFT's latest filing, from $911.6 million in the prior quarter.
- Across five years, EBT topped out at $911.6 million in Q4 2025 and bottomed at -$564.3 million in Q3 2025.
- Historically, EBT has averaged $5.1 million across 5 years, with a median of -$14.7 million in 2023.
- Annual changes were most pronounced in 2022 — EBT sank 1466.13% — and 2025, when it soared 4382.72%.
- Lakefront Biotherapeutics' EBT stood at -$64.6 million in 2022, then advanced by 28.77% to -$46.0 million in 2023, then soared by 144.21% to $20.3 million in 2024, then jumped by 4382.72% to $911.6 million in 2025, then sank by 98.21% to $16.3 million in 2026.
- Business Quant data shows LKFT's EBT at $16.3 million in Q1 2026, $911.6 million in Q4 2025, and -$564.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Lakefront Biotherapeutics | 1.89 Bn | 1.89 Bn | 3.51 Mn | -50.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.56 Mn |
| Mar 31, 2026 | 16.34 Mn |
| Dec 31, 2025 | 350.79 Bn |
| Sep 30, 2025 | -564.27 Mn |
| Jun 30, 2025 | 177.44 Mn |
| Mar 31, 2025 | -164.48 Mn |
| Dec 31, 2024 | -3.27 Bn |
| Sep 30, 2024 | -102.41 Mn |
| Jun 30, 2024 | 51.91 Mn |
| Mar 31, 2024 | 24.92 Mn |
| Dec 31, 2023 | 6.00 Bn |
| Sep 30, 2023 | -15.48 Mn |
| Jun 30, 2023 | -14.70 Mn |
| Mar 31, 2023 | -12.21 Mn |
| Dec 31, 2022 | -72.28 Bn |
| Sep 30, 2022 | -37.87 Mn |
| Jun 30, 2022 | -81.47 Mn |
| Mar 31, 2022 | -13.00 Mn |
| Dec 31, 2021 | 4.73 Mn |
| Sep 30, 2021 | -207.20 Mn |